GlobalData on MSN18d
BMS’ Phase II trial of CAR T cell therapy meets primary endpointBristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of differentiation 19 (CD19)-directed CAR T cell therapy, Breyanzi, met its primary ...
The differential diagnosis involves the recently identified IRF4/MUM1+ lymphomas, particularly in Waldeyer’s ring; t(14;18)-negative Grade 1/2 FLs; and nodal marginal zone lymphoma (NMZL).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback